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Abstract
Background: Increased left ventricular mass (LVM) is associated with adverse outcomes in patients receiving
chronic hemodialysis. Among patients receiving conventional hemodialysis (CHD, 3×/week, 4 hrs/session), we
evaluated whether dialysis intensification with in-centre nocturnal hemodialysis (INHD, 3×/week, 7-8 hrs/session in
the dialysis unit) was associated with regression of LVM.
Methods: We conducted a retrospective cohort study of CHD recipients who converted to INHD and received
INHD for at least 6 months. LVM on the first echocardiogram performed at least 6 months post-conversion was
compared to LVM pre-conversion. In a secondary analysis, we examined echocardiograms performed at least 12
months after starting INHD. The effect of conversion to INHD on LVM over time was also evaluated using a
longitudinal analysis that incorporated all LVM data on patients with 2 or more echocardiograms.
Results: Thirty-seven patients were eligible for the primary analysis. Mean age at conversion was 49 ± 12 yrs and
30% were women. Mean pre-conversion LVM was 219 ± 66 g and following conversion, LVM declined by 32 ± 58
g (p = 0.002). Among patients whose follow-up echocardiogram occurred at least 12 months following conversion,
LVM declined by 40 ± 56 g (p = 0.0004). The rate of change of LVM decreased significantly from 0.4 g/yr before
conversion, to -11.7 g/yr following conversion to INHD (p < 0.0001).
Conclusion: Conversion to INHD is associated with a significant regression in LVM, which may portend a more
favourable cardiovascular outcome. Our preliminary findings support the need for randomized controlled trials to
definitively evaluate the cardiovascular effects of INHD.
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Background
Patients with chronic kidney disease (CKD) who require
dialysis are at high risk of cardiovascular morbidity and
mortality [1]. Interventions that have been shown to
improve cardiovascular outcomes in the general popula-
tion have inconsistently demonstrated benefit in patients
receiving chronic dialysis [2-5]. This may be, in part,
due to the unique array of cardiovascular risk factors in
patients with end-stage renal disease (ESRD)[6].
Emerging data suggest that intensification of hemodialy-
sis (HD) through the provision of more frequent and/or
more prolonged sessions may reduce the high burden of
cardiovascular disease in this population [7,8] and
enhance survival [9,10]. Improved clinical outcomes may
be mediated by reduction in the extracellular fluid
volume and improved blood pressure control, enhanced
clearance of uremic toxins, or more consistent mineral
metabolic control [11-13].
While conventional HD (CHD) regimens are typically
thrice weekly with each dialysis session lasting 3-4
hours, more intensified schedules have taken advantage
of the nighttime for the administration of extended dia-
lysis sessions, thereby avoiding intrusion into productive
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home nocturnal HD (5-6 sessions per week, 7-8 hours
per session) conferred a regression in left ventricular
mass (LVM), a well-validated surrogate for clinical
events, as compared to individuals who remained on
CHD [7]. Unfortunately, only a minority of CHD
patients is capable of undertaking home nocturnal HD
and therefore these benefits of intensified HD may not
be available to the majority of the conventional HD
population.
In-centre nocturnal HD (INHD, 3 sessions per week,
7-8 hours per session) presents an alternative promising
approach to intensified dialysis, particularly for indivi-
duals with barriers to self-administered home HD
[14-19]. Although there is increasing interest in thrice
weekly INHD, there are limited data on the cardiovascu-
lar impact of this modality. In this study, we evaluated
the change in LVM, as measured by echocardiography,
in relation to the conversion from CHD to INHD.
Methods
This is a retrospective cross-over study of patients with
ESRD who converted from CHD to INHD at St.
Michael’s Hospital, a tertiary care academic hospital in
Toronto, Canada, from January 1, 2004 to September
30, 2009. The INHD Program at St. Michael’s Hospital
was initially instituted to accommodate chronic HD
patients who might benefit from an intensified dialysis
schedule but for whom there was a barrier to home dia-
lysis. Individuals with hemodynamic instability during
hemodialysis or poor mineral metabolic control on
CHD in addition to those with compelling socioeco-
nomic reasons (i.e., job preservation) for intensified noc-
turnal dialysis were preferentially referred for conversion
to INHD. With increasing availability of INHD at our
institution over time, patients receiving CHD who
expressed a desire to switch to INHD for any reason
were also considered. Patients who commenced INHD
before October 1, 2009 and continued INHD for at least
6 months following conversion from CHD were eligible
for inclusion in this study.
HD was administered in the CHD and INHD pro-
grams using the Gambro Phoenix (Gambro Inc, Rich-
mond Hill, ON) HD machine and Baxter Exeltra 210
and Xenium 210 dialyzers which contain cellulose tria-
cetate and polyethersulfone membranes, respectively
(Baxter Healthcare Corp., Mc-Gaw Park IL). Patients
who were on CHD received thrice weekly treatments of
3.5-4 hours duration with a target blood pump speed of
400 mL/min and dialysate flow rate of 500-800 mL/min.
INHD was performed for 7-8 hrs thrice weekly with a
dialysate flow rate of 500 mL/min and a target blood
pump speed of 300 mL/min. In both modalities, anticoa-
gulation was achieved with unfractionated heparin. A
standard calcium bath of 1.25 mmol/L was used in
CHD and was increased to 1.5 mmol/L when calcium-
based binders were reduced or eliminated following con-
version to INHD. When appropriate, diet was liberalized
and phosphate binders tapered once INHD commenced.
Patients were managed according to prevailing guide-
lines for blood pressure, hemoglobin, mineral metabo-
lism parameters and vascular access [20-25].
The St. Michael’s Hospital Research Ethics Board
approved the study and due to the retrospective nature
of the data collection, the requirement for informed
consent was waived.
Data collection
Clinical and demographic data were abstracted from the
hospital’s electronic information system and comple-
mented by information from a dedicated database that
tracks all patients in our HD program. For each labora-
tory value, the pre-conversion value was the mean of all
readings obtained during the three months prior to
INHD conversion. The post-conversion value comprised
the mean of values obtained during the three months
after the patient had been on INHD for 6 months and
12 months, respectively.
Echocardiographic data
We used hospital databases to identify all transthoracic
echocardiograms that were performed following the
initiation of chronic hemodialysis. Pre- and post- con-
version echocardiograms refer to the timing of the echo-
cardiogram in relation to the date of the first INHD
session. Echocardiographic data were systematically
gleaned from reports by a trained data collector. LVM
was the primary endpoint of this study; left ventricular
mass index was not consistently available as contem-
poraneous patient weight and height were not recorded
at the time of each echocardiographic examination.
Standardized echocardiographic examinations were
performed, including 2-dimensional, M-mode and Dop-
pler recordings. Exams were performed with high-qual-
ity commercially available echocardiographs equipped
with 2.0 to 2.5 MHz transducers (IE33 Philips Ultra-
sound). Exams were digitally recorded (XCelera Echo,
Philips Ultrasound) and reported off-line by highly-
experienced readers, blinded to clinical data. LVM was
calculated using an anatomically validated formula for
echocardiography [26,27] and did not include the papil-
lary muscles.
Statistical analyses
In our primary analysis, we considered all patients with
a pre-conversion echocardiogram at anytime between
the initiation of chronic dialysis until conversion to
INHD. These individuals were also required to have a
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of commencing INHD. A secondary analysis was
restricted to a sub-cohort of individuals with a post-con-
version echocardiogram that took place at least 12
months following the start of INHD. The paired t-test
was used to evaluate the changes in LVM and laboratory
measurements that were normally distributed. Labora-
tory measurements that were not normally distributed
were compared with the Wilcoxon signed rank test.
The impact of conversion to INHD was assessed in an
additional analysis by considering all available echocar-
diograms during each patient’s dialysis history. Patients
with at least 2 available echocardiograms at anytime
were considered in these analyses. The number of echo-
cardiograms ranged from 2 to 12 per patient. In analyz-
ing such repeated measures data, individual differences
in LVM were captured by random effects using growth
modeling. The random effects represent continuous var-
iation in growth from the patient’s first available LVM
and the change in LVM over time. In the within-patient
component of mixed model analyses, a piece-wise linear
model was used to estimate changes both before and
after conversion to INHD. In the between-patient com-
ponent of the analyses, we modeled the inter-individual
differences in LVM [28,29].
Statistical analyses were performed using SAS Version 9
(SAS Institute Inc., Cary, North Carolina). All p-values
were two-sided, and significance was set at a value of 0.05.
Systematic re-evaluation of the echocardiographic data
The data used in our primary and secondary analyses
were gleaned from reports of studies that were per-
formed on clinical grounds in the context of usual care
in our echocardiography laboratory. Since this approach
may have introduced excessive variability into the esti-
mation of LVM, a senior echocardiographer (H. L-P),
performed a systematic review of all the echocardio-
grams for which pre- an post-INHD images were retrie-
vable. The change in LVM following at least 6 months
on INHD (which parallels the primary analysis above)
was reported as a sensitivity analysis.
Results
Patient Characteristics
Fifty-six subjects initiated INHD between January 1,
2004 and September 30, 2009. Ten individuals were
excluded as the required echocardiograms were not
available. Nine people were excluded as they received
less than 6 months of INHD before changing to another
modality.
The characteristics of the 37 patients who were
included in the primary analysis are shown in Table 1.
Approximately 70% were men and the mean age was 49
± 12 years. The median time since the start of renal
replacement therapy was 4 years. The most common
cause of ESRD was glomerulonephritis (35%) and this
was followed by diabetes (32%). At the time of conver-
sion to INHD, approximately half of the patients were
dialyzed through an arteriovenous fistula. The majority
of patients had preserved left ventricular ejection frac-
tion prior to starting INHD.
Changes in hematologic and biochemical parameters
The per-session urea reduction ratio increased by six
months following the start of INHD and this was
Table 1 Description of patients converting to in-centre
nocturnal dialysis (n = 37)
Female (%) 11 (30)
Age at time of conversion, in years 49.0 ± 12.2
Ethnicity (%)
Caucasian 18 (49)
Black 4 (11)
Asian 3 (8)
Pacific Islander 8 (22)
Other 4 (11)
Etiology of ESRD (%)
Diabetes mellitus 12 (32)
Ischemic 2 (5)
Glomerulonephritis 13 (35)
Other 4 (11)
Unknown 6 (16)
Median time on dialysis pre-conversion (IQR), in years 4.0 (1.4-8.3)
Vascular access at time of conversion
Arteriovenous fistula 18 (49)
Arteriovenous graft 1 (2)
Central venous catheter 18 (49)
Pre-INHD conversion echocardiographic data
Left ventricular ejection fraction *
> 60% 26 (72)
40-59% 5 (14)
< 40% 5 (14)
LV end-diastolic dimension, in cm 4.9 ± 0.7
LV end-systolic dimension, in cm 3.3 ± 0.9
LV posterior wall thickness, in cm 1.2 ± 0.2
Interventricular septal wall thickness, in cm 1.2 ± 0.3
Patient weight, in kg 77.2 ± 19.9
Previous kidney transplant 13 (35)
Diabetes 17 (46)
History of coronary artery disease
# 8 (22)
History of cerebrovascular disease 2 (5)
History of cancer 6 (16)
Categorical variables are expressed as number (%) and continuous variables
are expressed as the mean ± standard deviation.
* Ejection fraction data missing for 1 patient
# Coronary artery disease was defined as a history of myocardial infarction,
coronary artery bypass graft or percutaneous coronary intervention.
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phosphate (1.57 ± 0.59 mmol/L at 6 months and 1.46 ±
0.47 mmol/L at 12 months post-conversion vs 2.10 ±
0.59 mmol/L pre-conversion, p < 0.0001 for both com-
parisons) and a rise in serum calcium (2.20 ± 0.12
mmol/L at 6 months post-conversion vs 2.12 ± 0.23
mmol/L pre-conversion, p = 0.03) following conversion
to INHD (Table 2). Conversion to INHD was not asso-
ciated with significant changes in intact parathyroid hor-
mone, serum albumin or hemoglobin.
Left ventricular mass in relation to INHD conversion
In the primary analysis, a 32 ± 58 gram decline in LVM
was observed following conversion to INHD (p =
0.0002) (Table 3). Some degree of LVM regression
occurred in 29 of 37 (78%) patients. Among 31 patients
who were eligible for the secondary analysis, which
required a follow-up echocardiogram at least 12 months
after conversion, the decline in LVM was greater (-40 ±
56 grams, p = 0.0004).
Our mixed model analysis included 184 studies from
40 patients who converted to INHD and had at least
two echocardiograms performed at anytime during their
dialysis history (Table 4). On average, before the conver-
sion date, there was no significant change (slope = 0.4 ±
2.5 g/year, p = 0.87) in LVM. After the conversion date,
there was a significant decrease in LVM (slope = -11.7 ±
3.1 g/year, p < 0.001). The annual change in LVM fol-
lowing conversion differed significantly from that before
the conversion date (-12.1 ± 7.8 g/year, p = 0.012).
Sensitivity analysis
We were able to retrieve the electronic images of pre-
and post-INHD conversion echocardiographic images in
17 individuals included in the primary analysis and
these were read by a single blinded echocardiographer.
As compared to values obtained before conversion to
INHD, the mean reduction in LVM obtained at least 6
months following INHD conversion was 31 ± 43 grams
(p = 0.001).
Discussion
We have previously shown that INHD is a feasible and
well-accepted form of renal replacement therapy for
patients with ESRD [14]. Our current study expands on
these findings by demonstrating that conversion to
INHD is associated with a significant regression in LVM.
Left ventricular hypertrophy (LVH) is common in
patients receiving chronic dialysis and is likely the con-
sequence of many factors that are prevalent in patients
with chronic kidney disease, including longstanding
hypertension, extracellular fluid volume expansion,
endothelial dysfunction, inflammation, oxidative stress
and altered mineral metabolism [30-32]. In the general
population as well as in those with ESRD, LVH is asso-
ciated with higher rates of cardiovascular events includ-
ing sudden death and arrhythmias [32]. Regression of
LVM has been associated with improved outcomes in
patients with and without ESRD [33-35].
There is a growing body of data suggesting that inten-
sified dialysis, as delivered through home nocturnal HD
Table 2 Selected laboratory values prior to INHD conversion and 6 and 12 months following INHD conversion
Pre-conversion
(n = 37)
Six months
following INHD conversion (n = 37)
Twelve months following INHD
conversion (n = 31)
Reduction in urea, % 71.7 ± 6.7 84.9 ± 6.3* 86.7 ± 6.4*
Hemoglobin, in g/L 114.5 ± 17.3 119.1 ± 14.8 117.1 ± 13.5
Serum albumin, in g/L 33.7 ± 3.5 33.3 ± 3.0 32.8 ± 4.4
Calcium, in mmol/L 2.12 ± 0.23 2.20 ± 0.12* 2.18 ± 0.17
Phosphate, in mmol/L 2.10 ± 0.59 1.57 ± 0.49* 1.46 ± 0.47*
PTH, in pmol/L 26 (20-41) 28 (15-74) 36 (17-61)
ALP, in Units/L 95 (63-138) 124 (105-167)* 144 (92-212)*
Data are presented as means ± standard deviation or medians (interquartile range), as appropriate. The paired t-test was used to compare pre- and post-
conversion differences for normally-distributed variables and the signed rank test was used for non-normally distributed variables.
* denotes p-value of < 0.05 for change in the laboratory value as compared to pre-conversion to INHD
Table 3 Changes in left ventricular mass following conversion to INHD
Analysis* Left ventricular mass (SD)
in grams while on CHD
Left ventricular mass (SD) in
grams after conversion to INHD
Change in LVM
(SD) in grams
p-value
Primary (n = 37) 219 ± 66 186 ± 69 -32 ± 58 0.002
Secondary (n = 31) 215 ± 71 174 ± 62 -40 ± 56 0.0004
*In both the primary and secondary analyses, the patient’s last available echocardiogram on conventional hemodialysis prior to conversion to INHD was
considered the pre-conversion study. In the primary analysis, the post-conversion echocardiogram was the first study occurring ≥ 6 months following conversion
to INHD. In the secondary analysis, the post-conversion echocardiogram was the first study occurring ≥ 12 months following conversion to INHD.
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regression. We hypothesized that these benefits may
extend to individuals receiving thrice weekly INHD. A
recently published cohort study suggested lower mortal-
i t ya n da2 4g / m
2 reduction in left ventricular mass
index after one year of INHD [18]. However, only about
one-third of patients underwent both baseline and fol-
low-up echocardiography. In the current study, we con-
firmed the association between conversion to INHD and
LVM regression after analyzing pre- and post-INHD
echocardiograms in the majority of our patients who
commenced INHD.
Despite the fact that INHD delivers less than half of the
total dialysis time administered through home nocturnal
regimens, the magnitude in LVM regression that we
observed was comparable to that achieved in studies that
demonstrated the benefits of home nocturnal hemodialy-
sis [7,36]. In a cohort study of 28 patients who com-
menced home nocturnal hemodialysis, Chan et al showed
a1 7g / m
2 reduction in indexed LVM at one year [36]. A
clinical trial in Alberta, Canada, demonstrated a 14 g
reduction in LVM after 6 months of nocturnal hemodia-
lysis [7]. The recently reported Frequent Hemodialysis
Network trial demonstrated a non-significant reduction
in LVM of 8 g after 1 year of home nocturnal hemodialy-
sis [37]. The more modest findings in the latter trial may
be related to the inclusion of recipients with a shorter
dialysis vintage and greater residual kidney function.
Overall, the advent of INHD may represent an important
means of providing intensified dialysis to the vast major-
ity of ESRD patients who would not be capable or would
be otherwise unwilling to adopt home HD [38]. Although
the cardiovascular benefits of intensified dialysis are likely
maximized by self-administration of therapy on most
nights of the week, three sessions per-week allows us to
provide therapy to more patients.
This study has several limitations. The commence-
ment of INHD was often dictated by clinical (eg, severe
hyperphosphatemia, hemodynamic lability on conven-
tional dialysis) or socioeconomic (eg, job preservation)
circumstances. As a result, applicability of our findings
to the broader hemodialysis population is not assured.
Since this was a retrospective review, the echocardio-
graphic data emanate from studies which were not car-
ried out at regular pre-defined intervals. Some INHD
recipients lacked pre- and/or post-conversion echocar-
diograms and could not be studied in our main analyses
while other patients had numerous studies, likely driven
by clinical circumstances. These factors may limit the
generalizability of our findings. We aimed to address
these factors by performing an analysis that accounted
for all echocardiograms in each individual with at least
two available studies. Using mixed models, we were able
to account for variable time intervals between studies.
Reassuringly, the significant post-INHD reduction in
LVM persisted when using this analytic approach.
We did not consider a control group of patients who
remained on CHD. While recent studies that evaluated
intensified dialysis attempted to identify matched con-
trols [10,19], such matching is often difficult as patients
who agree to intensify their dialysis regimen may be
inherently different than those who do not. Allowing
patients to serve as their own controls using a cross-
over design mitigates against confounding by patient-
specific characteristics that are often difficult to mea-
sure. Importantly, recent work has shown that LVM
generally increases with time in incident patients who
receive CHD [39]. In our patients who converted to
INHD, all aspects of routine dialysis care did not funda-
mentally change over time. This suggests that the echo-
cardiographic changes that we observed are likely the
result of dialysis intensification with INHD.
LVM estimated by echocardiographic methods has
limited precision and is susceptible to rapid changes in
extracellular fluid volume that occur during dialysis
[40]. The timing of the echocardiogram with respect to
dialysis was not standardized thereby causing inevitable
variability in the LVM estimates. Furthermore, some
echocardiograms may have been obtained for specific
clinical reasons, which could impact on the results we
obtained. While INHD provides more intensive dialysis,
the interdialytic interval remains essentially unchanged
from CHD, and thus interdialytic weight gain is less
likely to change following conversion to INHD. More-
over, the random relationship between the timing of
echocardiography and dialysis was present both before
and after conversion to INHD. As a result, there should
be no systematic bias that would impact on LVM esti-
mates in either phase of the study. In our main analyses,
echocardiograms were obtained over a timeframe of sev-
eral years and were interpreted by multiple readers. This
may have contributed to variability in the readings.
Table 4 Effect of INHD Conversion on Left Ventricular
Mass
Estimate
(Standard Error)
Level of LVM at the conversion date (g) 212.9 (9.9) *
Annual change in LVM before the INHD
conversion date (g/year)
0.4 (2.5)
Annual change in LVM following the INHD
conversion date (g/year)
-11.7 (3.1)*
Difference in annual change in LVM following and
prior to INHD conversion (g/year)
-12.1(4.8) *
The results are based on estimates from a mixed model analysis. They include
all patients who converted to INHD who had at least 2 echocardiograms
performed at anytime (n = 40). All available echocardiograms for these
patients were considered in these analyses (n = 184).
*=p<. 0 5
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senior echocardiographer reviewed all retrievable studies
confirmed a LVM reduction that was consistent with
the results obtained in the primary analysis.
Cardiac magnetic resonance provides accurate and
precise measurements of left ventricular structure
[41,42] and has been repeatedly employed as the metric
in trials of intensified dialysis [7,8,37,43]. Our group has
adopted cardiac magnetic resonance-derived LVM as
the primary outcome in an ongoing prospective evalua-
tion of the cardiovascular effects on INHD (Clinical-
Trials.gov registration NCT00718848). However,
echocardiography is logistically easier to perform, has no
contraindications, is far less expensive and remains the
most widely used modality for the assessment of cardiac
structure and function in clinical practice.
Irrespective of imaging technique, LVM regression is
still a surrogate outcome. Left ventricular size may
merely be reflective of the accumulated cardiovascular
toxicity of end-stage renal disease and regression of
LVM may indicate an attenuation of these effects. How-
ever, this does not imply that improvements in LVM are
causally associated with better clinical outcomes. A well-
designed randomized controlled trial that is based on
clinically-relevant endpoints (i.e., all-cause mortality and
adjudicated cardiovascular events) is required to provide
clinical meaning to our findings and help determine
whether the widespread adoption of intensified dialysis
modalities such as INHD is justified. To our knowledge,
there are no ongoing randomized trials exploring the
impact of INHD on hard clinical endpoints. Until such
studies are completed, observational studies using well-
validated surrogate endpoints such as LVM regression
provide valuable insights.
Finally, this study can not draw definitive conclusions
on the mechanisms through which INHD may mediate
LVM regression. Blood pressure lowering likely plays a
key role in the LVM regression seen following the initia-
tion of home nocturnal hemodialysis [7,36]. Others have
shown that INHD may also lead to a reduction in blood
pressure and/or the requirement for blood pressure-low-
ering medications [18,19]. Unfortunately, the retrospec-
tive nature of this study precluded the longitudinal
analysis of blood pressure values and antihypertensive
medication burden in relation to serial changes in LVM.
Other factors that may impact on changes in LV mass,
but which we were unable to capture, include dialysate
composition, dialysis adequacy (as defined by standard
Kt/Vurea), residual kidney function, interdialytic weight
gain and vascular access. Consideration of these factors
will be important in future studies examining the cardi-
ovascular impact of INHD.
Conclusions
Our preliminary findings extend previous work and raise
the possibility that the intensification of hemodialysis
with thrice weekly in-centre nocturnal hemodialysis
leads to a regression in left ventricular mass. If these
findings are confirmed by more rigorous prospective
studies, this may prompt a re-evaluation of the optimal
way in which hemodialysis should be delivered.
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